Humacyte
HUMA
70 hedge funds and large institutions have $38.7M invested in Humacyte in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 14 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.54% less ownership
Funds ownership: 13.05% → 11.51% (-1.5%)
10% less funds holding
Funds holding: 78 → 70 (-8)
10% less capital invested
Capital invested by funds: $43.1M → $38.7M (-$4.48M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
58% less call options, than puts
Call options by funds: $323K | Put options by funds: $767K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$755K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$513K |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$202K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$156K |
| 5 |
E
Ergoteles
New York
|
+$120K |
Top Sellers
HUMA Hedge Fund Activity: Q3 2022 in Review
70 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2022, worth a combined $38.7M — down 10% from $43.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of HUMA and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was Renaissance Technologies, adding an estimated $755K. The largest seller was York Capital Management Global Advisors, cutting an estimated $3.42M.
- 70 institutional investors held Humacyte (HUMA) as of Q3 2022, down from 78 in Q2 2022.
- Funds reported $38.7M of Humacyte stock for Q3 2022, down 10% quarter-over-quarter.
- 8 funds opened new Humacyte positions in Q3 2022 and 14 closed out, a net change of -6 holders.
- The largest Humacyte buyer in Q3 2022 was Renaissance Technologies, an estimated $755K added.
- The largest Humacyte seller in Q3 2022 was York Capital Management Global Advisors, an estimated $3.42M sold.
Based on aggregated 13F filings for Q3 2022.